LIBI Diagnostics is a gene-biomarker start-up for the early detection of cancer, powered by next-generation bio-liquid tests. Using state-of-the-art Next-Generation Sequencing (NGS) technology, LIBI-Diagnostics customizing tests for each patient by detecting alterations of Aurora Kinase A in blood and/or voided urine samples compared to the genomic expression data in the primary tumor. Libi-Diagnostics provides a practical and effective answer to the the inefficiency of periodic imaging tests. LIBI diagnoses recurrent cancerous development in an early stage with only few cells and provides sufficient information to neutralize that early development. In this way, it is possible to spare the patient aggressive treatments, unnecessary suffering and maintain his good chances of survival.